Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLO-316 in advanced or metastatic clear cell renal cell carcinoma
NCT04696731Phase 1Active, not recruiting
- Sponsor
- Allogene Therapeutics
- Start
- Feb 2021
- Primary completion
- Jan 2030
- Modality
- Gene Silencing, CRISPR-Cas9, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ALLO-316 in clear cell renal cell carcinoma (ccRCC), sponsored by Allogene Therapeutics. Primary endpoints: Dose Limiting Toxicities of ALLO-316 at 28 days and Dose Limiting Toxicities of ALLO-647 at 33 days. Started Feb 2021; status: active, not recruiting.
02
Drugs
ALLO-316
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT04696731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04696731.